These are good times for PerkinElmer (PKI).
The life sciences/pharma tool market is about as strong as it has ever
been, and the company's pivot toward diagnostics and services should pay
off in the years to come in the form of more revenue stability and
better margins. If management can reverse a pretty uninspiring
historical trend of underwhelming M&A integration and missing
long-term revenue and margin targets, the future could be pretty bright
for this company.
Read more here:
PerkinElmer Riding A Strong Cycle And Making Positive Long-Term Shifts
No comments:
Post a Comment